Pharmaceuticals

CMS released FY2025 9 Months earnings on March 16, 2026 (SGT) with actual revenue of SGD 1.107 B and actual EPS of SGD 0.091

CMS released FY2025 Q3 earnings on March 16, 2026, post-market (SGT), with actual revenue of SGD 381.46 M and actual EPS of SGD 0.0205

CMS released FY2025 Q4 earnings on March 16 During-Market (SGT), actual revenue SGD 386.48 M, actual EPS SGD 0.0207

CMS released FY2025 Annual Earnings on March 16 During-Market (SGT), actual revenue SGD 1.492 B (forecast SGD 1.516 B), actual EPS SGD 0.1118

CMS to release FY2025 earnings report on March 16, during market hours (SGT), with forecast revenue of SGD 1.525 B

CMS Subsidiary Dermavon Applying for Separate Listing

CMS released FY2025 Q1 earnings on August 18, 2025 (SGT) with actual revenue of SGD 369.58 M and EPS of SGD 0.0359

CMS released FY2025 Q2 earnings on August 18 During-Market (SGT), actual revenue SGD 356.12 M, actual EPS SGD 0.0346

CMS released FY2025 Semi-Annual Earnings on August 18 During-Market SGT, actual revenue SGD 725.7 M (forecast SGD 712.11 M), actual EPS SGD 0.0705

CMS to Release FY2025 Semi-Annual Earnings on August 18, 2025 (SGT), Forecast Revenue SGD 714.85 M

China Medical System Holdings Limited released FY2023 9 Months Earnings on April 2, 2025 (SGT) with actual revenue of SGD 1.194 B and EPS of SGD 0.1671

China Medical System Holdings Limited released FY2023 Q3 earnings on April 2, 2025 (SGT) with actual revenue of SGD 317.72 M and EPS of SGD 0.0182

China Medical System Holdings Limited released FY2023 Q4 earnings on April 2, 2025 (SGT) with actual revenue of SGD 316.37 M and EPS of SGD 0.0181

China Medical System Holdings Limited released FY2024 Q4 earnings on April 2, 2025, post-market (SGT), with actual revenue of SGD 359.55 M and actual EPS of SGD 0.0273

China Medical System Holdings Limited released FY2023 earnings on April 2, 2025 (SGT), actual revenue SGD 1.508 B (forecast SGD 1.696 B), actual EPS SGD 0.1842

China Medical System Holdings Limited released FY2024 9 Months Earnings on April 2, 2025 (SGT), with actual revenue of SGD 1.026 B and EPS of SGD 0.0965

China Medical System Holdings Limited released FY2024 Q3 earnings on April 2, 2025, post-market (SGT) with actual revenue of SGD 352.26 M and EPS of SGD 0.0268

China Medical System Holdings Limited released FY2024 earnings on April 2, 2025 (SGT), actual revenue SGD 1.387 B (forecast SGD 1.458 B), actual EPS SGD 0.1239

China Medical System Holdings Limited released FY2023 Q2 earnings on August 30, 2024 (SGT) with actual revenue of SGD 429.94 M and actual EPS of SGD 0.073

China Medical System Holdings Limited released FY2024 Q1 earnings on August 30 (SGT), actual revenue SGD 337.27 M, actual EPS SGD 0.0348

Clearbridge

Meituan MB eCW260804

Pacific RadianceW270919

Alibaba MB ePW261005

NKY 59000MBeCW260612

Mary Chia

Vins

Luxking

SIA MB eCW260930

P-Nova Short MSSG-1X USy

China Medical System Holdings Limited (CMS) announced that the New Drug Application (NDA) for its innovative drug MG-K10, aimed at treating Seasonal Allergic Rhinitis (SAR), has been accepted by China's National Medical Products Administration. The drug, also known as Comekibart Injection, is intended for adults with moderate-to-severe SAR not adequately controlled by intranasal corticosteroids. CMS holds exclusive commercialization rights for MG-K10, excluding its use for Atopic Dermatitis.

Asian Corporate Newswire

CMS; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

00867

DRMAW

DRMA

159892

520690

159506

159929

159849

513700

China Medical System Holdings (HK:0867) reported a 9.9% increase in turnover to RMB8.21 billion and an 8.3% rise in gross profit for 2025, despite a 10.5% drop in headline profit due to a one-off tax payment. The board proposed a higher dividend per share, supported by a strong cash position. Innovative products contributed nearly 60% of revenue, with a 44.1% sales increase in that segment. The company is expanding internationally, with plans for a separate Hong Kong listing for its Dermavon unit and a secondary listing in Singapore. Analysts rate the stock as a Buy with a target price of HK$17.00.

Tip Ranks

DERMATA THERAPEUTICS INC C/WTS (TO PUR COM)

Dermata Therapeutics

CS精准医

Geratherm Medical AG

Bosera Hang Seng Health Care ETF(QDII)

Direxion S&P Biotech Bear 3X

Direxion S&P Biotech Bull 3X

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

VanEck Biotech ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

VG Health

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal 800 Health Care ETF

iShares Global Healthcare

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

iShares Biotechnology ETF

Penghua CSI HK Connect Health Care Composite ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

China Medical System Lifts Revenue and Dividend as Innovation and Overseas Push Gather Pace

Zydus Lifesciences has received approval from China's National Medical Products Administration for its drug Desidustat, used to treat renal anaemia in Chronic Kidney Disease (CKD) patients. The drug has been licensed to CMS International Development and Management Ltd, a subsidiary of China Medical System Holdings. Zydus aims to improve patient outcomes and expand access to CKD treatment in Greater China, where over 120 million CKD patients exist. Desidustat is marketed in India as Oxemia, with over 100,000 patients treated since its launch in 2022.

Business Standard

Zydus drug Desidustat for renal anaemia gets regulatory nod in China

Insilico Medicine has partnered with China Medical System (CMS) to launch AI drug discovery collaborations targeting central nervous system (CNS) and autoimmune diseases. The collaboration will utilize Insilico's Pharma.AI platform for small-molecule design and candidate screening, combined with CMS's expertise in clinical development. Insilico will receive R&D funding for each program, aiming to streamline the drug development process and enhance clinical success rates. Both companies plan to deepen their collaboration in clinical strategy and global partnerships to improve patient access to innovative treatments.

Pharmaceutical Technology

Insilico and CMS launch drug discovery collaborations for CNS diseases

CMS(8A8.SG)

CMS; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

China Medical System Lifts Revenue and Dividend as Innovation and Overseas Push Gather Pace

Zydus drug Desidustat for renal anaemia gets regulatory nod in China

Insilico and CMS launch drug discovery collaborations for CNS diseases